ReviewBiomedicines2022
Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 7 citations in OpenAlex.
- Apparent Non-Response to Phosphodiesterase Type 5 Inhibitors in Erectile Dysfunction: A Narrative Review of Structured Reassessment and Management.Medicina (Kaunas, Lithuania) · 2026Review
- The Impact of Penile Prosthesis Type on Early Postoperative Pain: A Prospective Comparative Study.Journal of clinical medicine · 2026Article
- The Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualization.Journal of clinical medicine · 2026Review
- Erectile Function Before and After Elective Inguinal Hernia Repair: A Paired IIEF-5 Study Comparing Laparoscopic and Open Techniques.Journal of clinical medicine · 2026Article
- Uroselective Alpha-1A Blockade Versus Surgical De-Obstruction: Differential Associations with Heart Rate Variability Restoration and Symptom Relief in Benign Prostatic Hyperplasia with Bladder Outlet Obstruction.Life (Basel, Switzerland) · 2026Article
- Association Between Parameters of Penile Doppler Ultrasound and Cardiovascular Risk in Patients with Erectile Dysfunction: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Erectile Dysfunction and Its Impact on Health-Related Quality of Life in Prostate Cancer Patients: A Multicenter Cross-Sectional Study from Pakistan.Epidemiologia (Basel, Switzerland) · 2026Article
- Optilume Drug-Coated Balloon Dilation for Male Sphincteric (Membranous) Urethral Strictures: 53 Consecutive Cases.Journal of clinical medicine · 2025Article
- Using the International Index of Erectile Function-15 in Comparative Analysis Between Transcutaneous Electrical Nerve Stimulation of the Pudendal Nerve and Low-Level Laser Therapy in the Treatment of Erectile Dysfunction After COVID-19.Journal of clinical medicine · 2025Article
- Causal relationship between immune cells, inflammatory cytokines, metabolites, and erectile dysfunction: a two-sample Mendelian randomization study.Translational andrology and urology · 2024Article
- The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-Analysis of Observational Studies.Journal of clinical medicine · 2024Review
- Bayesian-based analysis of the causality between 731 immune cells and erectile dysfunction: a two-sample, bidirectional, and multivariable Mendelian randomization study.Sexual medicine · 2024Article
- Recent advances in stem cell therapy for erectile dysfunction: a narrative review.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.